CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), ...
Australian medicines regulator, the Therapeutic Goods Administration (TGA), has granted approval for mRESVIA (mRNA-1345), an ...
Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...
The risk for new-onset or recurrent AF was not increased among older adult patients with preexisting conditions following RSV vaccination.
The Royal Australian College of GPs (RACGP) has thrown its support behind Victoria's infant RSV vaccine program.Respiratory syncytial virus, or RSV ...
An Australian-first study demonstrating the effectiveness of a new immunization against respiratory syncytial virus (RSV) for ...
The Royal Australian College of GPs (RACGP) has thrown its support behind Victoria's infant RSV vaccine program. Respiratory syncytial virus, or RSV ...
Starting this spring, the Respiratory Syncytial Virus (RSV) vaccine will be available to adults aged 60 years and older residing in congregate living facilities, such as long-term care homes and ...
Shares in Moderna, Vaxcyte, Novavax and BioNTech all fell Monday after Peter Marks, head of the FDA office that reviews ...
Vietnam Investment Review on MSN1d
AIM Vaccine Cuts 2024 Losses by 90%, Paving the Way for Breakthrough GrowthAIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published its 2024 Annual Results announcement on March 30, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback